Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA)…
Analysts Are Bullish On 89bio’s NASH Data Slated For Early Next Year
Earlier today, 89bio Inc (NASDAQ:ETNB) concluded enrollment in ENLIVEN Phase 2b trial of pegozafermin for non-alcoholic steatohepatitis (NASH), enabling topline results in…
89bio Shares Climb After Concluding Enrolment In Mid-Stage NASH Study
89bio (NASDAQ: ETNB) has completed enrollment in ENLIVEN, the Phase 2b trial of pegozafermin for the treatment of non-alcoholic steatohepatitis (NASH).
Analyst Ratings for 89bio
Within the last quarter, 89bio (NASDAQ:ETNB) has observed the following analyst ratings:
6 Analysts Have This to Say About 89bio
Analysts have provided the following ratings for 89bio (NASDAQ:ETNB) within the last quarter:
Where 89bio Stands With Analysts
Analysts have provided the following ratings for 89bio (NASDAQ:ETNB) within the last quarter:
HC Wainwright & Co. Maintains Buy on 89bio, Raises Price Target to $27
HC Wainwright & Co. analyst Ed Arce maintains 89bio (NASDAQ:ETNB) with a Buy and raises the price target from $26 to $27.
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers
Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday’s Mid-Day Session
Gainers
Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year.